Food and Drug Administration (FDA) has not approved Epitalon for the treatment of insomnia or any sleep disorder, though the FDAs Pharmacy Compounding Advisory Committee has scheduled a review of Epitalon for insomnia as of 2026
Persistent nausea, early satiety, bloating, or constipation may lead to reduced treatment satisfaction and contribute to therapy interruption or discontinuation
EBioMedicine 84 , 104258 (2022)
In the central nervous system (CNS), GLP-1s may impact neuronal function in conditions, such as Alzheimer's disease and Parkinson's disease, through multiple mechanisms
Alternatively, serine can be converted to glycine for glutathione synthesis [48,49]
While injectable GLP-1s set the current gold standard in terms of results, pills expand access to this important class of therapy and for many patients, thats a meaningful win